HeXun Biosciences Co., Ltd. (TPEX:6986)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.50
-0.80 (-1.24%)
Apr 29, 2026, 1:20 PM CST
-16.34%
Market Cap 2.96B
Revenue (ttm) 293.23M
Net Income (ttm) 111.91M
Shares Out 46.00M
EPS (ttm) 2.43
PE Ratio 26.46
Forward PE n/a
Dividend 0.22 (0.34%)
Ex-Dividend Date n/a
Volume 7,712
Average Volume 111,370
Open 64.20
Previous Close 64.30
Day's Range 63.30 - 64.20
52-Week Range 50.00 - 78.60
Beta -0.28
RSI 65.29
Earnings Date Aug 13, 2026

About HeXun Biosciences

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 53
Stock Exchange Taipei Exchange
Ticker Symbol 6986
Full Company Profile

Financial Performance

In 2025, HeXun Biosciences's revenue was 293.23 million, an increase of 2.38% compared to the previous year's 286.42 million. Earnings were 111.91 million, a decrease of -23.99%.

Financial Statements

News

There is no news available yet.